CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas — Stella

Recruiting

Back to T-Cell Non-Hodgkin Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

China

Beijing GoBroad Hospital, Beijing

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai Liquan Hospital, Shanghai

Key details

Phase

Early testing / Safety & dosing

Sponsor

Beijing GoBroad Hospital

Collaborators

Ruijin Hospital, Shanghai Liquan Hospital

Enrollment target

~36 participants

Started

June 2025

Primary completion

June 2026

Age range

14 Years – 70 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov